Abstract
Pharmaceutical giants Novartis and GlaxoSmithKline (GSK) agreed in late April to swap some assets, with Novartis handing off its vaccine business to GSK and getting most of the British company's cancer portfolio in return.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have